&nbsp;

DiagnosticMedicalSonographerWorksheet

Dec 1969

Document

DiagnosticImagingClinicalIndicationforScanandPriorityLevelExamples

Dec 1969

Document

DiagnosticImagingDefinitions

Dec 1969

Regimen

DHAP+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

ODB - General Benefit

dexamethasone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Regimen

DCRBDOXO

Cancer Type:

Sarcoma,

Soft Tissue

Intent: Adjuvant, Curative, Palliative

Drugs Used:

dacarbazine,

DOXOrubicin

Quick Link(s):

Regimen Monograph

Regimen

AZCTVENE

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Palliative

Funding:

New Drug Funding Program

Azacitidine in combination with Venetoclax (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

venetoclax - Venetoclax in combination with azacitidine - Previously untreated acute myeloid leukemia

Drugs Used:

azaCITIDine,

venetoclax

Quick Link(s):

Regimen Monograph

Regimen

DEXAPOMA+ISAT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

New Drug Funding Program

Isatuximab - In Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Exceptional Access Program

pomalidomide - In combination with isatuximab and dexamethasone for relapsed or refractory multiple myeloma, according to specific criteria

Drugs Used:

Quick Link(s):

Regimen Monograph

Regimen

DEXASELI

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

selinexor (Unfunded),

dexamethasone

Quick Link(s):

Regimen Monograph

Document

ABVD.pdf

Sep 2020

Document

ABVD-FR.pdf

Sep 2020

Regimen

ACAL

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), according to clinical criteria

Drugs Used:

acalabrutinib

Quick Link(s):

Regimen Monograph

Jul 2024

Regimen

ACAL+OBIN

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

acalabrutinib (Unfunded),

oBINutuzumab (Unfunded)